%PDF-1.4
%
1 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 109>>stream
xs
w3T04PI2P0T5T0 q̍,Br4\rSRS*-L
́cKL\RSsR4C@@\C d
endstream
endobj
4 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 109>>stream
xs
w3T04PI2P0T5T0 q̍,Br4\rSRS*-L
́cKL\RSsR4C@@\C d
endstream
endobj
3 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 109>>stream
xs
w3T04PI2P0T5T0 q̍,Br4\rSRS*-L
́cKL\RSsR4C@@\C d
endstream
endobj
6 0 obj
<>stream
application/pdf
10.1080/14656566.2017.1419186
en
Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction
Ileana Antohe
Sabina A. Antoniu
Cristina Gavrilovici
Taylor & Francis
Expert Opinion on Pharmacotherapy, 2017. doi:10.1080/14656566.2017.1419186
COPD
inhaled therapy
fluticasone furoate
umeclidinium
vilanterol
triple inhaled therapy
Journal
Expert Opinion on Pharmacotherapy
© 2017 Informa UK Limited, trading as Taylor & Francis Group
1465-6566
1744-7666
00
00
1
3
10.1080/14656566.2017.1419186
https://doi.org/10.1080/14656566.2017.1419186
VoR
2017-12-21T05:22:13+05:30
Arbortext Advanced Print Publisher 11.0.3433/W Unicode
2017-12-22T04:37:40-08:00
2017-12-22T04:37:40-08:00
COPD; inhaled therapy; fluticasone furoate; umeclidinium; vilanterol; triple inhaled therapy
iText 4.2.0 by 1T3XT
uuid:059342f1-1846-40b3-8286-efc4cbdafd82
uuid:e64a5c0d-4b23-4000-8d2b-ae29eeaedb27
2017-12-22truewww.tandfonline.com10.1080/14656566.2017.1419186www.tandfonline.comtrue2017-12-2210.1080/14656566.2017.1419186
endstream
endobj
7 0 obj
<>stream
x+ |
endstream
endobj
8 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
9 0 obj
<>stream
x+ |
endstream
endobj
10 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS*
R
endstream
endobj
16 0 obj
<>stream
xYKϯG|?`y>>k#GSU"==J9HtbUUğ6A=^vy*tP9$Q?v_UU=mڻTk,QyVSE}'cܽ1cÝJU[{3)VfU=xoĿ2kٝx]˶藉vNsazw}4pIw?Lj ^ljM`b"WݷT0&sj3g;;gVOm>BjLrB|hh`gO5-IZlRڠ k<=K*WVߩw/7߾R|_)EP?ݏy10>
.;i[un/vLWT!6 BM,
@<:f9Efqeku(֨d15PsFZ@Y2Jf}DGEEۃA$<twu|e##
eUu
p Վ( W-˚<V7UJ3B@:=ftގֆ~t'7ݶ+rdmm!Wmr&lHM겳T&)ɋ̤M2LIp!q"aX"OKq:I^yчNRQeX]'P
ya K36NyKi/E/FGgтx5tup
|/A^"MH{>aa;nD鍨urLpZN]%'ߍ= _O$ր[3`h ã?@+s4`d5Ge%[ډ Sy![")!ن|~:% K3o#]ZI\цB1[RY+,@`N7c4
)y6IbyNhϨᒴ0+5N}v
߆*dT9o!#f!'Coq.x/H
@6:Rj@';ϴ7$eXȔI;ҁŬEU_WiYV#1dASecQΨ@wq 4Ddm{@Tqp!GDo82o=z